# EDGAR Filing Document

**Accession Number:** 0001955217
**File Stem:** 0001022079-23-000015
**Filing Date:** 2023-2
**Character Count:** 7431
**Document Hash:** f49fa8be0f2f4ab647fd9c4f38ec1e42
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001022079-23-000015.hdr.sgml**: 20230216

**ACCESSION NUMBER**: 0001022079-23-000015

**CONFORMED SUBMISSION TYPE**: 3/A

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20221116

**FILED AS OF DATE**: 20230216

**DATE AS OF CHANGE**: 20230216

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** KUPPUSAMY KARTHIK
- **CENTRAL INDEX KEY:** 0001955217

**FILING VALUES:**
- **FORM TYPE:** 3/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-12215
- **FILM NUMBER:** 23638868

**MAIL ADDRESS:**
- **STREET 1:** 500 PLAZA DRIVE
- **STREET 2:** C/O QUEST DIAGNOSTICS INC
- **CITY:** SECAUCUS
- **STATE:** NJ
- **ZIP:** 07094
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** QUEST DIAGNOSTICS INC
- **CENTRAL INDEX KEY:** 0001022079
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **IRS NUMBER:** 161387862
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 500 PLAZA DRIVE
- **CITY:** SECAUCUS
- **STATE:** NJ
- **ZIP:** 07094
- **BUSINESS PHONE:** 9735202700

**MAIL ADDRESS:**
- **STREET 1:** 500 PLAZA DRIVE
- **CITY:** SECAUCUS
- **STATE:** NJ
- **ZIP:** 07094

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CORNING CLINICAL LABORATORIES INC
- **DATE OF NAME CHANGE:** 19960903

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3/A

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>KUPPUSAMY KARTHIK<br><sub>(Last) (First) (Middle)</sub><br>500 PLAZA DRIVE<br>C/O QUEST DIAGNOSTICS INC<br><sub>(Street)</sub><br>SECAUCUS, NJ 07094<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2022-11-16 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_SVP, Clinical Solutions_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>QUEST DIAGNOSTICS INC [ DGX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock |  |  |  |  |  |  |  | 7960 | D |  |
| Common Stock |  |  |  |  |  |  |  | 1396<sup>(1)</sup> | I | 401(k) |
| Common Stock |  |  |  |  |  |  |  | 358 | I | By Trust |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Non-Qualifed Stock Option (right to buy) | $86.63 |  |  |  |  |  |  | <sup>(2)</sup> | 2029-02-18 | Common Stock | 3045.0 |  |  | D |  |
| Non-Qualifed Stock Option (right to buy) | $112.17 |  |  |  |  |  |  | <sup>(2)</sup> | 2030-02-18 | Common Stock | 5224.0 |  |  | D |  |
| Non-Qualifed Stock Option (right to buy) | $121.805 |  |  |  |  |  |  | <sup>(2)</sup> | 2031-02-17 | Common Stock | 4827.0 |  |  | D |  |
| Non-Qualifed Stock Option (right to buy) | $127.725 |  |  |  |  |  |  | <sup>(2)</sup> | 2032-02-24 | Common Stock | 3320.0 |  |  | D |  |
| Non-Qualifed Stock Option (right to buy) | $140.39 |  |  |  |  |  |  | <sup>(2)</sup> | 2032-08-10 | Common Stock | 3212.0 |  |  | D |  |

---

### Footnotes:

(1) These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under the Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.

(2) The options vest in three equal annual installments beginning on the first annual anniversary of the grant date.

**Remarks:**
This Form 3/A amends the original Form 3 filed on November 22, 2022, which inadvertently omitted (due to administrative error) 358 shares held indirectly by the Reporting Person through a family trust. This Form 3/A is also deemed to amend the Form 4 filed by the Reporting Person on February 1, 2023 to include the shares omitted from the original Form 3. In this regard, as of the date of this filing, the Reporting Person directly holds 8,005 shares and holds indirectly 1,769 shares.

**Signature:** William J. O'Shaughnessy, Jr., Attorney in Fact for Karthik Kuppusamy  
**Date:** 2023-02-16

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**